+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07808827

Phase III Randomized Study Comparing JS203 Plus Chemotherapy to Rituximab Plus Chemotherapy in RelapsedRefractory Diffuse Large B-Cell Lymphoma

Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-10-14

282

Participants Needed

1

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of glofitamab JS203 combined with chemotherapy drugs gemcitabine and oxaliplatin JS203-GemOx compared with rituximab combined with the same chemotherapy R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL. This is a randomized, open-label, phase III clinical trial conducted across multiple centers. Participants receive either JS203 with gemcitabine and oxaliplatin or rituximab with gemcitabine and oxaliplatin. The chemotherapy is given in 8 cycles every 3 weeks, while JS203 is given weekly in the first cycle and every 3 weeks thereafter, for up to one year. The trial compares these two treatment combinations to assess outcomes. During the study, participants undergo evaluations including survival tracking for up to about 24 months, and assessments of tumor response and adverse events for up to about 15 months. Researchers monitor overall survival, response rates, duration of response, and safety measures. The total study duration spans several years, with ongoing monitoring to assess treatment effects and safety.

CONDITIONS

Brief Title

A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Research Team

N

Niannian Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here